As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a “very conservative” way to model the fallout would be removing the eight reference markets from future product forecasts. More:
read moreWhile Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs of leveling off, the company still topped Wall Street estimates in 2026’s first quarter, buoyed by the impressive performance of branded drugs like Austedo, Uzedy and Ajovy. More:
read more
Partnership to support selection of first neoantigen therapy candidate More: Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy Source: News
read more
Collaboration aims to create integrated platform from discovery to IND submission More: BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development Source: News
read moreImmunology med Skyrizi charted sales growth of 30.9% over 2026’s first quarter, bringing in $4.48 billion as AbbVie’s top earner. More: AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde Source: fierce
read moreAs regulatory delays continue to plague Regeneron’s Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 billion for the first time since the second quarter of 2018. More: Regeneron's quarterly sales of Eylea drop below B
read more© 1994 - 2026 B.M. Pharmaceuticals